Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. NightHawk Biosciences, Inc.
  6. Summary
    NHWK   US42237K4094

NIGHTHAWK BIOSCIENCES, INC.

(NHWK)
  Report
Delayed Nyse  -  04:00 2022-06-27 pm EDT
2.650 USD   +7.72%
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
GL
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
AQ
06/06NIGHTHAWK BIOSCIENCES : CONSENT OF INDEPENDENT ACCOUNTANTS - Form 8-K/A
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/21/2022 06/22/2022 06/23/2022 06/24/2022 06/27/2022 Date
2.55(c) 2.64(c) 2.56(c) 2.46(c) 2.65(c) Last
63 436 32 992 53 593 43 781 62 768 Volume
+3.24% +3.53% -3.03% -3.91% +7.72% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3,18 M - -
Net income 2022 -32,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,15x
Yield 2022 -
Sales 2023 3,80 M - -
Net income 2023 -35,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,62x
Yield 2023 -
Capitalization 68,0 M 68,0 M -
Capi. / Sales 2022 21,4x
Capi. / Sales 2023 17,9x
Nbr of Employees 49
Free-Float 94,8%
More Financials
Company
Nighthawk Biosciences, Inc., formerly Heat Biologics, Inc., is a fully integrated biopharmaceutical company. The Company specializes in the end-to-end development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. It focuses on drug development through its integrated ecosystem of subsidiary companies, which includes Skunkworx Bio... 
Read more
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Ratings of NightHawk Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NIGHTHAWK BIOSCIENCES, INC.
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer..
GL
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer..
AQ
06/06NIGHTHAWK BIOSCIENCES : CONSENT OF INDEPENDENT ACCOUNTANTS - Form 8-K/A
PU
06/06NIGHTHAWK BIOSCIENCES, INC. Completion of Acquisition or Disposition of Assets, Financ..
AQ
05/16NIGHTHAWK BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
05/16NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/16NightHawk Biosciences Provides First Quarter 2022 Business Update
GL
05/11NORTH AMERICAN MORNING BRIEFING : All Eyes on Key -2-
DJ
05/10NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PT..
GL
05/10NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PT..
AQ
05/03NIGHTHAWK BIOSCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y..
AQ
05/03Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Unde..
GL
05/03Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Unde..
AQ
05/03Heat Biologics, Inc. will Change its Ticker to NHWK from HTBX
CI
05/03Heat Biologics, Inc. will Change its Name to NightHawk Biosciences, Inc
CI
More news
News in other languages on NIGHTHAWK BIOSCIENCES, INC.
05/16NightHawk Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
05/03Heat Biologics, Inc. va changer son ticker de HTBX à NHWK
04/19Heat Biologics va changer de nom pour devenir NightHawk Biosciences et adopter un nouve..
04/19Richard Myers devient président du conseil consultatif sur les bio-menaces de NightHawk
04/18L'unité Heat Biologics prévoit une nouvelle installation de bioproduction au Kansas
More news
Analyst Recommendations on NIGHTHAWK BIOSCIENCES, INC.
More recommendations
Chart NIGHTHAWK BIOSCIENCES, INC.
Duration : Period :
NightHawk Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NIGHTHAWK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,65 $
Average target price 12,90 $
Spread / Average Target 387%
EPS Revisions
Managers and Directors
Jeff A. Wolf Chairman, President & Chief Executive Officer
William L Ostrander Chief Financial Officer, Secretary & Controller
Matthew M. Seavey Senior Director-Research
Guillermo Arana Executive Director-Clinical Development
John James Monahan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NIGHTHAWK BIOSCIENCES, INC.-19.08%63
MERCK KGAA-27.40%75 582
KYOWA KIRIN CO. LTD.-1.44%12 291
SK BIOPHARMACEUTICALS CO., LTD.-24.07%4 429
BETTA PHARMACEUTICALS CO., LTD.-22.00%3 828
YUHAN CORPORATION-10.95%2 936